OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program
Stock Information for Coeptis Therapeutics Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.